Navigation Links
Preliminary report on antidepressants published
Date:6/10/2009

On 10 June 2009, the Institute for Quality and Efficiency in Health Care (IQWiG) presented the preliminary results of its benefit assessment of certain newer antidepressants. The project commissioned by the Federal Joint Committee (G-BA) is concerned with assessing the benefit of three agents, reboxetine, mirtazapine and bupropion XL in adult patients with depression, according to the German drug approval status. Interested parties and institutions may submit written comments on the preliminary report up until 9 July.

Reboxetine: no proof of benefit

The assessment produced different results for the three agents. According to a literature search performed by the Institute, reboxetine (manufacturer: Pfizer) was tested in at least 16 trials on approximately 4600 patients with depression. However, the Institute only had access to data on approximately 1600 of these patients. If the unpublished data are not included, there is a high risk of incorrectly estimating the benefit and harm of this agent. IQWiG has therefore come to the preliminary conclusion that no proof of benefit from treatment with reboxetine can be deduced from the data currently available.

Mirtazapine: results must be viewed with reservation

In the search for trials on mirtazapine (Essex Pharma), it was found that this agent had been tested in at least 31 trials that could be potentially relevant to the report. However, the Institute only had access to 27 evaluable trials. As it is also possible in this case that the results of the assessment may change if all data became available, all results presented by the Institute must be viewed with reservation.

In numerous comparisons with other antidepressants, mirtazapine showed no proof of superiority. Only when compared to placebo was there proof that in acute treatment more patients experienced an improvement of depression when they were treated with mirtazapine. However, the prognosis for a full recovery was no better in the mirtazapine group than in the placebo group. In addition, it was shown that patients treated with mirtazapine discontinue treatment more often due to side effects (adverse events) than patients treated with placebo or with some of the other antidepressants.

Bupropion: proof of benefit

The search identified 6 trials on bupropion XL (up to 300 mg/d) and the Institute was given access to the complete clinical study reports by the manufacturer, GlaxoSmithKline. There was proof of benefit for this agent compared to placebo in acute therapy and in the prevention of relapse into seasonal affective disorder, while on the other hand the data provided no indications of harm. The only antidepressant that was compared with bupropion XL in trials was venlafaxine XR. Bupropion XL showed inferiority to venlafaxine XR in acute therapy. Further information can be found in the executive summary of the preliminary report (see below).

Unpublished data contain the potential for deception

If not all available study data are available, this can lead to a strongly biased assessment. This potential for deception is of fundamental importance to all researchers who systematically assess drugs and other medical technologies. The experience of the Institute shows that voluntary self-commitment cannot be relied upon. The Institute therefore considers it an urgent necessity to make it compulsory by law for study sponsors to register clinical trials before commencement and publish the results soon after study completion. IQWiG's position is described in a second press release.


'/>"/>

Contact: Dr. Anna Sabine Ernst
anna-sabine.ernst@iqwig.de
049-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Amylin Announces Preliminary Results of Annual Meeting of Stockholders
2. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
3. Air Methods Preliminary 1st Qtr. Results Exceed Expectations
4. Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
5. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
6. Cynosure Announces Preliminary Financial Results for the First Quarter of 2009
7. National All Schedules Prescription Electronic Reporting (NASPER) Bill Receives Preliminary Funding
8. NBTY to Webcast Presentation at B. Riley & Co. Annual Las Vegas Institutional Investor Conference; Announces Preliminary Unaudited Net Sales Results for February 2009
9. HealthSouth Issues Preliminary Comments on the Presidents Healthcare Budget Proposal and Announces Plans to Host a Conference Call
10. PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results
11. NBTY Announces Preliminary Unaudited Net Sales Results for January 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
Breaking Medicine Technology: